Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

[Persistent aphthous mouth ulcers associated with tocilizumab: two cases].

Samimi M, Lauferon F, Hüttenberger B, Vaillant L, Goupille P, Machet L.

Ann Dermatol Venereol. 2013 Feb;140(2):120-4. doi: 10.1016/j.annder.2012.11.006. Epub 2012 Dec 25. French.

PMID:
23395494
4.

[Tocilizumab in rheumatoid arthritis].

Rueda Gotor J, Blanco Alonso R.

Reumatol Clin. 2011 Mar;6S3:S29-32. doi: 10.1016/j.reuma.2011.01.001. Epub 2011 Mar 23. Review. Spanish.

5.

Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

McLaughlin M, Östör A.

Expert Opin Drug Saf. 2015 Mar;14(3):429-37. doi: 10.1517/14740338.2015.998198. Epub 2015 Jan 2. Review.

PMID:
25553607
6.

Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.

Navarro-Millán I, Singh JA, Curtis JR.

Clin Ther. 2012 Apr;34(4):788-802.e3. doi: 10.1016/j.clinthera.2012.02.014. Epub 2012 Mar 22. Review.

7.

Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.

Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N.

Mod Rheumatol. 2014 Jan;24(1):26-32. doi: 10.3109/14397595.2013.854080.

PMID:
24261755
8.

Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.

Mitchell E, Jones G.

Expert Rev Clin Immunol. 2016;12(2):103-14. doi: 10.1586/1744666X.2016.1127159. Epub 2016 Jan 28.

PMID:
26629984
9.

Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.

Song SN, Yoshizaki K.

Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):307-16. doi: 10.1517/17425255.2015.992779. Epub 2014 Dec 10. Review.

PMID:
25491492
10.

Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.

Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, Hoshi D, Sato E, Yamanaka H.

Mod Rheumatol. 2014 May;24(3):399-404. doi: 10.3109/14397595.2013.843757. Epub 2013 Nov 5.

PMID:
24252045
11.

Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.

Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, Kawai S, Kawakami A, Koike T, Miyahara H, Miyamoto T, Munakata Y, Murasawa A, Nishimoto N, Ogawa N, Ojima T, Sano H, Shi K, Shono E, Suematsu E, Takahashi H, Tanaka Y, Tsukamoto H, Nomura A; MUSASHI Study Investigators.

J Rheumatol. 2015 May;42(5):799-809. doi: 10.3899/jrheum.140665. Epub 2015 Apr 1.

PMID:
25834203
12.

Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.

Patel AM, Moreland LW.

Drug Des Devel Ther. 2010 Oct 1;4:263-78. doi: 10.2147/DDDT.S14099. Review.

13.

Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.

Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y.

Mod Rheumatol. 2014 May;24(3):405-9. doi: 10.3109/14397595.2013.844294. Epub 2013 Oct 21.

PMID:
24252016
14.

Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums.

Navarro G, Taroumian S, Barroso N, Duan L, Furst D.

Semin Arthritis Rheum. 2014 Feb;43(4):458-69. doi: 10.1016/j.semarthrit.2013.08.001. Epub 2013 Nov 18.

PMID:
24262929
15.

Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.

Machado SH, Xavier RM.

Expert Opin Drug Saf. 2017 Apr;16(4):493-500. doi: 10.1080/14740338.2017.1303479. Review.

PMID:
28277841
16.

Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.

Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, Son Y, Inaba M, Nomura S.

J Rheumatol. 2013 Jul;40(7):1074-81. doi: 10.3899/jrheum.121389. Epub 2013 May 1.

PMID:
23637318
17.

Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab.

Cantarini L, Lopalco G, Vitale A, Coladonato L, Rigante D, Lucherini OM, Lapadula G, Iannone F.

Clin Rheumatol. 2015 Jun;34(6):1141-3. doi: 10.1007/s10067-014-2589-z. Epub 2014 Apr 15.

PMID:
24733249
18.

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials.

Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M.

Ann Rheum Dis. 2014 Jan;73(1):95-100. doi: 10.1136/annrheumdis-2013-203559. Epub 2013 Jun 13.

19.

Supplemental Content

Support Center